Mayako Michino

Mayako Michino

Auto-generated profile, based on publicly available information

Mayako Michino

Sanders Tri-Institutional Therapeutics Discovery Institute , 1230 York Ave.

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2023 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
WCWei Chen
Wei Chen
DCDi Cui
Di Cui
SJSteven V. Jerome
Steven V. Jerome
MMMayako Michino
Mayako Michino
ELEelke B. Lenselink
Eelke B. Lenselink
LWLingle Wang
Lingle Wang

2 September 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
YLYiman Liu
Yiman Liu
QLQinglan Li
Qinglan Li
FAFatemeh Alikarami
Fatemeh Alikarami
DBDeclan R. Barrett
Declan R. Barrett
LMLeila Mahdavi
Leila Mahdavi
LWLiling Wan
Liling Wan
The chromatin reader eleven–nineteen leukemia (ENL) has been identified as a critical dependency in acute myeloid leukemia (AML), but its therapeutic potential remains unclear. We describe a potent and orally bioavailable small-molecule inhibitor of ENL, TDI-11055, which displaces ENL from chromatin by blocking its YEATS domain interaction with acylated histones. Cell lines and primary patient samples carrying MLL rearrangements or NPM1 mutations are responsive to TDI-11055. A CRISPR-Cas9–mediated mutagenesis screen uncovers an ENL mutation that confers resistance to TDI-11055, validating the compound's on-target activity. TDI-11055 treatment rapidly decreases chromatin occupancy of ENL-associated complexes and impairs transcription elongation, leading to suppression of key oncogenic gene expression programs and induction of differentiation. In vivo treatment with TDI-11055 blocks disease progression in cell line– and patient-derived xenograft models of MLL-rearranged and NPM1-mutated AML. Our results establish ENL displacement from chromatin as a promising epigenetic therapy for molecularly defined AML subsets and support the clinical translation of this approach. Significance: AML is a poor-prognosis disease for which new therapeutic approaches are desperately needed. We developed an orally bioavailable inhibitor of ENL, demonstrated its potent efficacy in MLL-rearranged and NPM1-mutated AML, and determined its mechanisms of action. These biological and chemical insights will facilitate both basic research and clinical translation. This article is highlighted in the In This Issue feature, p. 2483

8 September 2023 in ACS Bio & Med Chem Au
Verified
Journal Article
Open access
MMMayako Michino
Mayako Michino
ABAlexandre Beautrait
Alexandre Beautrait
NBNicholas A. Boyles
Nicholas A. Boyles
ANAparna Nadupalli
Aparna Nadupalli
ADAlexey Dementiev
Alexey Dementiev
JVJeremie Vendome
Jeremie Vendome
Lpd (lipoamide dehydrogenase) in Mycobacterium tuberculosis (Mtb) is required for virulence and is a genetically validated tuberculosis (TB) target. Numerous screens have been performed over the last decade, yet only two inhibitor series have been identified. Recent advances in large-scale virtual screening methods combined with make-on-demand compound libraries have shown the potential for finding novel hits. In this study, the Enamine REAL library consisting of ∼1.12 billion compounds was efficiently screened using the GPU Shape screen method against Mtb Lpd to find additional chemical matter that would expand on the known sulfonamide inhibitor series. We identified six new inhibitors with IC50 in the range of 5-100 μM. While these compounds remained chemically close to the already known sulfonamide series inhibitors, some diversity was found in the cores of the hits. The two most potent hits were further validated by one-step potency optimization to submicromolar levels. The co-crystal structure of optimized analogue TDI-13537 provided new insights into the potency determinants of the series.

2 June 2021 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
IMIgor Maksimovic
Igor Maksimovic
EFEfrat Finkin-Groner
Efrat Finkin-Groner
YFYoshiyuki Fukase
Yoshiyuki Fukase
Qingfei ZhengQingfei Zheng
Qingfei Zheng
SSShan Sun
Shan Sun
YDYael David
Yael David
Tracking the esterase activity of DJ-1 via a fluorescent-based scalable assay to uncover and develop candidates with enhanced potency.

12 March 2024 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MMMayako Michino
Mayako Michino
TKTanweer A. Khan
Tanweer A. Khan
MMMichael W. Miller
Michael W. Miller
YFYoshiyuki Fukase
Yoshiyuki Fukase
JVJeremie Vendome
Jeremie Vendome
DHDavid J. Huggins
David J. Huggins

21 December 2022 in ChemRxiv
Verified
Preprint
Open access
PDF file
WCWei Chen
Wei Chen
DCDi Cui
Di Cui
SJSteven V. Jerome
Steven V. Jerome
MMMayako Michino
Mayako Michino
ELEelke B. Lenselink
Eelke B. Lenselink
LWLingle Wang
Lingle Wang
In the hit identification stage of drug discovery, a diverse chemical space needs to be explored to identify initial hits. Contrary to empirical scoring functions, absolute protein-ligand binding free energy perturbation (ABFEP) provides a theoretically more rigorous and accurate description of protein-ligand binding thermodynamics and could in principle greatly improve the hit rates in virtual screening. In this work, we describe an implementation of an accurate and reliable ABFEP method in FEP+. We validated the ABFEP method on eight congeneric compound series binding to eight protein receptors including both neutral and charged ligands. For ligands with net charges, the alchemical ion approach is adopted to avoid artifacts in electrostatic potential energy calculations. The calculated binding free energies are highly correlated with experimental results with the weighted average of R2 of 0.55 for the entire dataset and an overall RMSE of 1.1 kcal/mol when protein reorganization effect upon ligand binding was accounted for. Through ABFEP calculations using apo versus holo protein structures, we demonstrated that the protein conformational and protonation state changes between the apo and holo proteins are the main physical factors contributing to the protein reorganization free energy manifested by the overestimation of raw ABFEP calculated binding free energies using the holo structures of the proteins. Furthermore, we performed ABFEP calculations in three virtual screening applications for hit enrichment. ABFEP greatly improves the hit rates as compared to docking scores or other methods like metadynamics. The highly accurate ABFEP results demonstrated in this work position it as a useful tool to improve the hit rates in virtual screening, thus facilitate hit discovery.